Introduction: Fasting and postprandial hypertriglyceridemia are essential features of metabolic syndrome. Statins decrease fasting lipid levels but fail to reduce fat load induced hypertriglyceridemia. We established whether ezetimibe combined with simvastatin differently influences post fat load lipid levels and lipoprotein composition its compared to simvastatin 80 mg monotherapy in obese male metabolic syndrome patients. Methods: Prospective. randomized. double blind. crossover trial. Male obese metabolic syndrome (ATPIII) patients (n = 19) were treated with simvastatin 80 mg and simvastatin/ezetimibe 10 mg/10 mg for 6 weeks. At the start of the Study and after each treatment period oral fat loading, tests were performed. Lipoprotein fra...
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of stati...
AbstractObjectivesThe clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor...
OBJECTIVE: The combination of simvastatin, an HMG-CoA reductase inhibitor, and ezetimibe, an inhibit...
The postprandial lipid metabolism in metabolic syndrome patients is disturbed and may add to the inc...
Introduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Stati...
BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of ...
Patients with dyslipoproteinemia constitute the largest risk group for development of atherosclerosi...
Postprandial triglyceride (TG) levels are easy to measure and are associated with future cardiovascu...
Background: Ezetimibe specifically blocks the absorption of dietary and biliary cholesterol and plan...
SummaryBackground and purposeIt remains undetermined whether the addition of ezetimibe to ongoing st...
We appreciate the interest that Kostapanos et al has shown in our study ‘‘Effect of atorvastatin mon...
of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and at...
SummaryBackgroundOxidized low-density lipoprotein (LDL) cholesterol is a sensitive lipid marker for ...
International audienceStatin therapy reduces low-density lipoprotein (LDL) cholesterol levels and th...
BACKGROUND AND OBJECTIVE: One of the problems associated with reaching the low-density lipoprotein c...
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of stati...
AbstractObjectivesThe clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor...
OBJECTIVE: The combination of simvastatin, an HMG-CoA reductase inhibitor, and ezetimibe, an inhibit...
The postprandial lipid metabolism in metabolic syndrome patients is disturbed and may add to the inc...
Introduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Stati...
BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of ...
Patients with dyslipoproteinemia constitute the largest risk group for development of atherosclerosi...
Postprandial triglyceride (TG) levels are easy to measure and are associated with future cardiovascu...
Background: Ezetimibe specifically blocks the absorption of dietary and biliary cholesterol and plan...
SummaryBackground and purposeIt remains undetermined whether the addition of ezetimibe to ongoing st...
We appreciate the interest that Kostapanos et al has shown in our study ‘‘Effect of atorvastatin mon...
of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and at...
SummaryBackgroundOxidized low-density lipoprotein (LDL) cholesterol is a sensitive lipid marker for ...
International audienceStatin therapy reduces low-density lipoprotein (LDL) cholesterol levels and th...
BACKGROUND AND OBJECTIVE: One of the problems associated with reaching the low-density lipoprotein c...
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of stati...
AbstractObjectivesThe clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor...
OBJECTIVE: The combination of simvastatin, an HMG-CoA reductase inhibitor, and ezetimibe, an inhibit...